000 01413 a2200385 4500
005 20250517204306.0
264 0 _c20190506
008 201905s 0 0 eng d
022 _a1545-5017
024 7 _a10.1002/pbc.27039
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSimon, Nicolas
245 0 0 _aShould we replace etoposide phosphate by etoposide for allogeneic hematopoetic stem-cell transplantation in children?
_h[electronic resource]
260 _bPediatric blood & cancer
_c07 2018
300 _ae27039 p.
_bdigital
500 _aPublication Type: Letter
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aAntineoplastic Agents, Phytogenic
_xadministration & dosage
650 0 4 _aChild
650 0 4 _aEtoposide
_xadministration & dosage
650 0 4 _aHematologic Diseases
_xtherapy
650 0 4 _aHematopoietic Stem Cell Transplantation
650 0 4 _aHumans
650 0 4 _aOrganophosphorus Compounds
_xadministration & dosage
650 0 4 _aPrognosis
650 0 4 _aTransplantation Conditioning
650 0 4 _aTransplantation, Homologous
700 1 _aBarnoud, Delphine
700 1 _aBruno, Bénédicte
700 1 _aVasseur, Michèle
700 1 _aBéné, Johana
700 1 _aOdou, Pascal
773 0 _tPediatric blood & cancer
_gvol. 65
_gno. 7
_gp. e27039
856 4 0 _uhttps://doi.org/10.1002/pbc.27039
_zAvailable from publisher's website
999 _c28168294
_d28168294